Moderna's mRNA Pipeline Expansion Drives Growth Potential Beyond COVID-19 Vaccines
Moderna (MRNA) is transitioning from its reliance on COVID-19 vaccine revenue toward a diversified pipeline of mRNA-based therapeutics. The company recently achieved significant clinical milestones, including the approval of mFLUSIVA for influenza and breakthrough Phase 3 results for its personalized cancer vaccine, intismeran autogene, when used in combination with Merck's (MRK) Keytruda. While these developments position Moderna as a potential leader in oncology and infectious diseases through 2026, the stock faces valuation scrutiny. Despite massive recent gains, Wall Street analysts maintain a cautious outlook, with an average price target significantly below current trading levels due to concerns over its $90 billion market capitalization.